Galapagos (GLPG)
(Delayed Data from NSDQ)
$27.00 USD
-0.02 (-0.07%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $27.01 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
GLPG 27.00 -0.02(-0.07%)
Will GLPG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GLPG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GLPG
Down -9.97% in 4 Weeks, Here's Why You Should You Buy the Dip in Galapagos (GLPG)
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
GLPG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress
Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
Other News for GLPG
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
Galapagos Unveils Promising Cancer Therapy Data
Morgan Stanley Sticks to Its Hold Rating for Galapagos (GLPG)
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Agios Pharma (AGIO) and Viking Therapeutics (VKTX)
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024